{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:23:37Z","timestamp":1788398617214,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11934-023-01173-6","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T03:30:57Z","timestamp":1687923057000},"page":"455-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Michael J.","family":"Jalfon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om V.","family":"Sakhalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5260-766X","authenticated-orcid":false,"given":"Soum D.","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur U.","family":"Choksi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"1173_CR1","unstructured":"Surveillance E, End Results (SEER) Program (https:\/\/www.seer.cancer.gov). National Cancer Institute.: Cancer Stat Facts: Common Cancer Sites., 2022."},{"key":"1173_CR2","unstructured":"Surveillance E, End Results (SEER) Program (https:\/\/www.seer.cancer.gov). National Cancer Institute.: Cancer stat facts: prostate cancer., 2022."},{"key":"1173_CR3","unstructured":"(ACS) ACS: Cancer facts & Figures. Atlanta, Georgia, 2022."},{"issue":"3","key":"1173_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.37549\/ARO1243","volume":"9","author":"JR Broughman","year":"2020","unstructured":"Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Management of oligometastatic prostate cancer. Appl Radiat Oncol. 2020;9(3):6.","journal-title":"Appl Radiat Oncol."},{"key":"1173_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/PPO.0000000000000418","volume":"26","author":"EN Kinsey","year":"2020","unstructured":"Kinsey EN, Zhang T, Armstrong AJ. Metastatic hormone-sensitive prostate cancer: a review of the current treatment landscape. Cancer J. 2020;26:64\u201375.","journal-title":"Cancer J"},{"key":"1173_CR6","unstructured":"National Comprehensive Cancer Network: Prostate Cancer (Version 4.2022)."},{"key":"1173_CR7","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.2147\/OTT.S228355","volume":"13","author":"ME Hall","year":"2020","unstructured":"\u2022 Hall ME, Huelster HL, Luckenbaugh AN, et al. Metastatic hormone-sensitive prostate cancer: current perspective on the evolving therapeutic landscape. Onco Targets Ther. 2020;13:3571\u201381. A succinct review of four chemotherapy, novel androgen receptor targeting agents in the treatment of mPCa.","journal-title":"Onco Targets Ther"},{"key":"1173_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.14735\/amko201997","volume":"32","author":"J Navr\u00e1til","year":"2019","unstructured":"Navr\u00e1til J, Poprach A, Lakom\u00fd R, et al. Oligometastatic prostate cancer. Klin Onkol. 2019;32:97\u2013100.","journal-title":"Klin Onkol"},{"key":"1173_CR9","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.21037\/tau-20-1033","volume":"10","author":"S Mahjoub","year":"2021","unstructured":"Mahjoub S, Heidenreich A. Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review. Transl Androl Urol. 2021;10:3167\u201375.","journal-title":"Transl Androl Urol"},{"key":"1173_CR10","doi-asserted-by":"crossref","unstructured":"Rao A, Vapiwala N, Schaeffer EM, et al. Oligometastatic prostate cancer: a shrinking subset or an opportunity for cure? Am Soc Clin Oncol Educ Book. 2019:309\u201320.","DOI":"10.1200\/EDBK_239041"},{"key":"1173_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrurol.2016.175","volume":"14","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15\u201325.","journal-title":"Nat Rev Urol"},{"key":"1173_CR12","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3109\/0284186X.2013.764010","volume":"52","author":"U Schick","year":"2013","unstructured":"Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and\/or distant metastases. Acta Oncol. 2013;52:1622\u20138.","journal-title":"Acta Oncol"},{"key":"1173_CR13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fonc.2012.00172","volume":"2","author":"KA Ahmed","year":"2012","unstructured":"Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.","journal-title":"Front Oncol"},{"key":"1173_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clgc.2012.08.003","volume":"11","author":"P Berkovic","year":"2013","unstructured":"Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27\u201332.","journal-title":"Clin Genitourin Cancer"},{"key":"1173_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"1173_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"1173_CR17","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1089\/end.2009.0587","volume":"24","author":"PC Sprenkle","year":"2010","unstructured":"Sprenkle PC, Mirabile G, Durak E, et al. The effect of argon gas pressure on ice ball size and rate of formation. J Endourol. 2010;24:1503\u20137.","journal-title":"J Endourol"},{"key":"1173_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1464-410X.2005.05502.x","volume":"95","author":"JG Baust","year":"2005","unstructured":"Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 2005;95:1187\u201391.","journal-title":"BJU Int"},{"key":"1173_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bju.12512","volume":"113","author":"O Ukimura","year":"2014","unstructured":"Ukimura O, de Castro Abreu AL, Hung AJ, et al. Cryosurgery for clinical T3 prostate cancer. BJU Int. 2014;113:684\u20135.","journal-title":"BJU Int"},{"key":"1173_CR20","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.juro.2012.06.014","volume":"188","author":"JL Chin","year":"2012","unstructured":"Chin JL, Al-Zahrani AA, Autran-Gomez AM, et al. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c\u2013T3b). J Urol. 2012;188:1170\u20135.","journal-title":"J Urol"},{"key":"1173_CR21","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.juro.2008.07.108","volume":"180","author":"RJ Babaian","year":"2008","unstructured":"Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180:1993\u20132004.","journal-title":"J Urol"},{"key":"1173_CR22","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.7150\/thno.67530","volume":"12","author":"K Kwak","year":"2022","unstructured":"Kwak K, Yu B, Lewandowski RJ, et al. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation. Theranostics. 2022;12:2175\u2013204.","journal-title":"Theranostics"},{"key":"1173_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2008.10.126","volume":"58","author":"MS Sabel","year":"2009","unstructured":"Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009;58:1\u201311.","journal-title":"Cryobiology"},{"key":"1173_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","volume":"194","author":"R Satkunasivam","year":"2015","unstructured":"Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol. 2015;194:378\u201385.","journal-title":"J Urol"},{"key":"1173_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.kjms.2017.07.002","volume":"33","author":"MX Sheng","year":"2017","unstructured":"Sheng MX, Wan LL, Liu CM, et al. Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: a retrospective analysis. Kaohsiung J Med Sci. 2017;33:609\u201315.","journal-title":"Kaohsiung J Med Sci"},{"key":"1173_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12957-021-02455-4","volume":"19","author":"M Sheng","year":"2021","unstructured":"Sheng M, Guo S, Liu C. Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis. World J Surg Oncol. 2021;19:345.","journal-title":"World J Surg Oncol"},{"key":"1173_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41391-021-00335-2","volume":"24","author":"N Wang","year":"2021","unstructured":"Wang N, Ye Y, Deng M, et al. Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study. Prostate Cancer Prostatic Dis. 2021;24:837\u201344.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1173_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29:1235\u201348.","journal-title":"Ann Oncol"},{"key":"1173_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41391-019-0176-8","volume":"23","author":"AE Ross","year":"2020","unstructured":"Ross AE, Hurley PJ, Tran PT, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:184\u201393.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1173_CR30","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.2217\/fon-2021-1424","volume":"18","author":"Y Li","year":"2022","unstructured":"Li Y, Wang N, Zhao D, et al. Cytoreductive prostate cryoablation and metronomic cyclophosphamide for metastatic hormone-sensitive prostate cancer. Future Oncol. 2022;18:2373\u201380.","journal-title":"Future Oncol"},{"key":"1173_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1173_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10\u20138.","journal-title":"J Urol"},{"key":"1173_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00345-019-02661-6","volume":"38","author":"T Daly","year":"2020","unstructured":"Daly T. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World J Urol. 2020;38:565\u201391.","journal-title":"World J Urol"},{"key":"1173_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13014-021-01776-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P, Roach M III, Schmidt-Hegemann NS, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16:50.","journal-title":"Radiat Oncol"},{"key":"1173_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JU.0000000000001376","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT, Breau RH, Chou R, et al. Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART II. J Urol. 2021;205:22\u20139.","journal-title":"J Urol"},{"key":"1173_CR36","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353\u201366.","journal-title":"Lancet"},{"key":"1173_CR37","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"1173_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"\u2022 Boev\u00e9 LMS, Hulshof M, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial. Eur Urol. 2019;75:410\u20138. Outlines the results of the HORRAD trial investigating radiation therapy for patients with mPCa.","journal-title":"Eur Urol"},{"key":"1173_CR39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/iju.14567","volume":"28","author":"R Aizawa","year":"2021","unstructured":"Aizawa R, Takayama K, Nakamura K, et al. Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: a combination of prostate-targeted treatment and metastasis-directed therapy. Int J Urol. 2021;28:749\u201355.","journal-title":"Int J Urol"},{"key":"1173_CR40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/jrr\/rraa056","volume":"62","author":"K Inaba","year":"2021","unstructured":"Inaba K, Tsuchida K, Kashihara T, et al. Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer. J Radiat Res. 2021;62:511\u20136.","journal-title":"J Radiat Res"},{"key":"1173_CR41","first-page":"490","volume":"35","author":"SV Dandapani","year":"2020","unstructured":"Dandapani SV, Wong J, Twardowski P. Review of radium-223 and metastatic castration-sensitive prostate cancer. Cancer Biother Radiopharm. 2020;35:490\u20136.","journal-title":"Cancer Biother Radiopharm"},{"key":"1173_CR42","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bju.15055","volume":"125","author":"W Ranasinghe","year":"2020","unstructured":"\u2022\u2022 Ranasinghe W, Chapin BF, Kim IY, et al. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU Int. 2020;125:792\u2013800. This review outlines ongoing clinical trials investigating cytoreductive prostatectomy in mPCa and provides a concise explanation of expected results and perspective into trial components.","journal-title":"BJU Int"},{"key":"1173_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/pcan.2016.63","volume":"20","author":"M Moschini","year":"2017","unstructured":"Moschini M, Morlacco A, Kwon E, et al. Treatment of M1a\/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis. 2017;20:117\u201321.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1173_CR44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.prnil.2018.10.002","volume":"7","author":"BE Yuh","year":"2019","unstructured":"Yuh BE, Kwon YS, Shinder BM, et al. Results of phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate Int. 2019;7:102\u20137.","journal-title":"Prostate Int"},{"key":"1173_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.prnil.2022.03.001","volume":"10","author":"IY Kim","year":"2022","unstructured":"\u2022 Kim IY, Mitrofanova A, Panja S, et al. Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate International. 2022;10:75\u20139. The results of the phase I clinical trial SIMCAP, a novel trial in cytoreductive prostatectomy, which leads to phase 2\/3 clinical trial.","journal-title":"Prostate International"},{"key":"1173_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bju.15669","volume":"130","author":"P Sooriakumaran","year":"2022","unstructured":"Sooriakumaran P, Wilson C, Rombach I, et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int. 2022;130:43\u201353.","journal-title":"BJU Int"},{"key":"1173_CR47","doi-asserted-by":"publisher","first-page":"e042953","DOI":"10.1136\/bmjopen-2020-042953","volume":"11","author":"MJ Connor","year":"2021","unstructured":"Connor MJ, Shah TT, Smigielska K, et al. Additional treatments to the local tumour for metastatic prostate cancer-assessment of novel treatment algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open. 2021;11:e042953.","journal-title":"BMJ Open"},{"key":"1173_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13992","volume":"121","author":"WS Jang","year":"2018","unstructured":"Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2018;121:225\u201331.","journal-title":"BJU Int"},{"key":"1173_CR49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bju.15553","volume":"129","author":"S Buelens","year":"2022","unstructured":"Buelens S, Poelaert F, Claeys T, et al. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int. 2022;129:699\u2013707.","journal-title":"BJU Int"},{"key":"1173_CR50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","volume":"193","author":"A Heidenreich","year":"2015","unstructured":"Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193:832\u20138.","journal-title":"J Urol"},{"key":"1173_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.urology.2019.03.040","volume":"131","author":"T Lan","year":"2019","unstructured":"Lan T, Chen Y, Su Q, et al. Oncological outcome of cytoreductive radical prostatectomy in prostate cancer patients with bone oligometastases. Urology. 2019;131:166\u201375.","journal-title":"Urology"},{"key":"1173_CR52","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/pros.24170","volume":"81","author":"S Si","year":"2021","unstructured":"Si S, Zheng B, Wang Z, et al. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - a retrospective cohort study and meta-analysis. Prostate. 2021;81:736\u201344.","journal-title":"Prostate"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-023-01173-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-023-01173-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-023-01173-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T06:11:20Z","timestamp":1696227080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-023-01173-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1007\/s11934-023-01173-6","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"assertion":[{"value":"9 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No conflict\/competing interests for any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}